|
|
Commercial Insight: Asthma and COPD - Control is the GoalPublished by: Datamonitor Published: Oct. 21, 2004 - 90 Pages Table of ContentsTABLE OF CONTENTS CHAPTER 1 EXECUTIVE SUMMARY 3 Objective of the analysis 3 Datamonitor insight into the disease market 3 CHAPTER 2 MARKET DEFINITION AND OVERVIEW 8 Market definition for this report 8 Current market situation 9 Strategic scoping and focus 15 CHAPTER 3 COUNTRY MARKET ASSESSMENTS 16 Current and future opportunities and threats in the asthma/COPD market 16 Global opportunities and threats 16 Opportunities 16 Threats 19 US: opportunities and threats 24 Opportunities 24 Threats 25 Japan: opportunities and threats 27 Opportunities 27 Threats 28 France: opportunities and threats 31 Opportunities 31 Threats 32 Germany: opportunities and threats 32 Opportunities 32 Threats 33 Italy: opportunities and threats 34 Opportunities 34 Threats 34 Spain: opportunities and threats 36 Opportunities 36 Threats 36 UK: opportunities and threats 37 Opportunities 37 Threats 39 CHAPTER 4 FORECAST ANALYSIS 42 Assumptions and events 42 Combination class 43 Oral anti-inflammatories class 54 Long & short B2-agonist class 55 Anti-muscarinic class 57 Biological class 58 Limitations of data 59 Forecasts 60 CHAPTER 5 COMMERCIAL IMPACT AND LIFECYCLE MANAGEMENT: CASE STUDIES 61 Introduction 61 Case studies 61 Advair - redefining the approach to asthma management 61 Sepracor - building a primary care presence 65 APPENDIX A - MARKET DATA AND MAJOR BRAND KEY FACTS 70 Global disease market data 70 Combination ICS/LABA 71 Oral non-steroidal anti-inflammatories 73 Inhaled corticosteroids 74 Long-acting bronchodilators 76 Long-acting anti-cholinergics 78 Combination anticholinergic/short-acting b2 agonists 79 Short-acting anticholinergics 80 APPENDIX B 81 Bibliography 81 Glossary 86 Report methodology 87 About Datamonitor 88 About Datamonitor Healthcare 88 About the Respiratory & Infectious Diseases analysis team 89 Disclaimer 90 AbstractIntroductionThe world market for asthma/COPD drugs, valued at $13.3 billion in 2003, is forecast to grow to $19.0 billion by 2009, driven by the expansion of combination steroid/bronchodilator products into a wider spectrum of patients, and strong growth in COPD specific therapies. GlaxoSmithKline and Merck remain the indisputable leaders in asthma, with Pfizer steadily building a presence in COPD. Scope Outlook for the asthma/COPD market, including key events impacting combination products, leukotriene antagonists, and anticholinergics Global sales forecasts to 2014, including country-specific forecasts for the US, Japan, France, Germany, Italy, Spain and the UK Review of global and country specific opportunities and threats impacting key brands, including Seretide, Symbicort, Singulair, Spiriva, and Daxas Case studies on Seretide's promotional strategies on redefining asthma management, and building Xopenex's primary care presence Highlights GSK has added fresh impetus to Seretide growth by focusing on the control of asthma, rather than symptom severity, enabling Seretide to appeal to the full spectrum of patients and move beyond moderate to severe asthma. The growth of Spiriva and Daxas will add breadth to an underdeveloped market and establish Pfizer as the premier company in COPD, which is the fastest growing segment of the market. Landmark morbidity and mortality trials, improved awareness, diagnosis and earlier therapeutic intervention, indicates a very promising outlook for this disease. The dominance of Seretide and Singulair is not likely to be challenged in the foreseeable future, although the large market size, with few NCEs, makes it possible for companies to successfully launch niche products through effective patient targeting. Reasons to Purchase Evaluate the expansion of combination products into a wider spectrum of patients through new indications and promotional activities Quantify the future size and scope of the asthma/COPD market and predict the future performance of key compounds Examine the impact of future patent expiries in each of the seven country markets Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||